BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, December 12, 2025
See today's BioWorld
Home
» Surprise! Allergan sheds generics unit for branded focus in $40.1B Teva deal
To read the full story,
subscribe
or
sign in
.
Surprise! Allergan sheds generics unit for branded focus in $40.1B Teva deal
July 28, 2015
By
Jennifer Boggs
In an unexpected move, Allergan plc divested its global generic business to Teva Pharmaceuticals Industries Ltd. for $40.5 billion, continuing its evolution into an innovative pharma firm.
BioWorld
